Chemotargets, a CataloniaBio & HealhTech member, has appointed Scott Boyer as new CEO with the aim to consolidate its business transition from a software business to a biotechnology company. 

Boyer has a PhD in Molecular Toxicology from the University of Colorado (US). He joins Chemotargets from Swedish pharmaceutical company Klaria. Prior he was CSO at AstraZeneca in Sweden and senior scientist at Pfizer Central Research in the US.

Boyer’s short-term goals include closing the Series A funding round opened in July.

Genesis Biomed is advising Chemotargets in the transformation of the company.

More information

Photo: Scott Boyer - © Chemotargets

You may also be interested in:

• Chemotargets opens a round of investment up to €15 million
• Alliance between Chemotargets and IMIM for new cancer therapies